# Treatment with Mirvetuximab-Soravtansin—first clinical experience in advanced ovarian cancer in a comprehensive cancer center

## TL;DR

This study reports on the use of Mirvetuximab-Soravtansin in treating advanced ovarian cancer, showing some positive responses and manageable side effects.

## Contribution

The paper presents the first clinical experience with Mirvetuximab-Soravtansin in a comprehensive cancer center for advanced ovarian cancer.

## Key findings

- CA-125 levels decreased in all evaluable patients after treatment.
- Two patients showed partial response, and one had partial remission at stage IV.
- One patient experienced transient ocular toxicity as an adverse event.

## Abstract

Mirvetuximab-Soravtansin (MIRV) is an antibody–drug conjugate (ADC) for the therapy of advanced platinum-resistant folate receptor α (FRα)-expressing ovarian cancer. The goal of the study was to treat patients with MIRV off-label in our Comprehensive Cancer Center regarding the outcome and adverse events.

This retrospective single-center cohort study included six patients with advanced high-grade serous ovarian cancer (HGSOC) or high-grade serous primary peritoneal carcinoma (PPC) with initial FIGO stage IIC–IV between July 2023 and August 2024. Inclusion criteria were metastatic advanced HGSOC or PPC, expression of FRα ≥75% (IHC PS2+), and progression during systemic therapy with ≥3 therapies before. All patients underwent ophthalmological examination before therapy with MIRV.

After 2–6 cycles of MIRV (median, 3.3), objective descriptive response with computed tomography (CT) scan of the thorax–abdomen and CA-125 response were monitored. CA−125 decreased in all evaluable patients (n, 5) from baseline. In the CT scan, two patients showed radiographically stable disease, and one of our patients represented progressive disease. Two patients revealed a partial response, and one of them had partial remission at the initial FIGO stage IV. Adverse events were monitored; one patient developed transient ocular toxicity.

Treatment with MIRV has been shown to be promising in advanced ovarian cancer. In a small heterogeneous group of heavily pretreated patients, general recommendations for therapy with MIRV are limited. Close collaboration with ophthalmology and patient education is essential to mitigate ocular events.